Prosecution Insights
Last updated: November 04, 2026
Application No. 17/368,697

DEVICES AND METHODS FOR LIGHT-DIRECTED POLYMER SYNTHESIS

Non-Final OA §103
Filed
Jul 06, 2021
Priority
Jul 07, 2020 — provisional 63/048,888
Examiner
HANDY, DWAYNE K
Art Unit
1798
Tech Center
1700 — Chemical & Materials Engineering
Assignee
TWIST BIOSCIENCE Corporation
OA Round
4 (Non-Final)
63%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
480 granted / 762 resolved
-2.0% vs TC avg
Strong +25% interview lift
Without
With
+24.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
23 currently pending
Career history
791
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
41.7%
+1.7% vs TC avg
§102
27.5%
-12.5% vs TC avg
§112
19.0%
-21.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 762 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/23/26 has been entered. Response to Arguments Applicant’s arguments, filed 06/23/26, with respect to the rejection of claims under 35 U.S.C. 103 as being unpatentable over Rothberg et al. (US 2015/0141268) in view of Walt et al. (US 6,377,721) have been fully considered and are persuasive. Applicant has amended claims 1 and 44 to include the limitation of a synthesis surface having a plurality of nucleosides attached wherein each nucleoside comprises a photolabile protecting group and then argued this feature is not taught or suggested by the cited prior art. See pages 7-8 of Applicant’s Remarks and the attached Interview Summary. The Examiner agrees; therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made below. Inventorship This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-3, 5, 6, 10, 13, 16, 18 and 43-53 are rejected under 35 U.S.C. 103 as being unpatentable over Rothberg et al. (US 2015/0141268) in view of Walt et al. (US 6,377,721), and further in view of Fodor et al. (US 5,424,186). Rothberg teaches an active source pixel integrated device for detection and analysis of biological and chemical compounds. The embodiments of the device most relevant to the instant claims are shown in Figures 3-1 to 3-7F. Regarding claims 1-3, 16, 45 and 53 - As shown in Figures 3-1 to 3-7F, Rothberg teaches a device for polymer synthesis, comprising: a solid support, wherein the solid support comprises a plurality of wells (3-210), wherein each of the wells comprises: a) a synthesis surface (3-211) located in a bottom region of each of the wells; b) a light-emitting layer (3-245) in addressable communication with the synthesis surface and situated below the synthesis surface; and c) a CMOS driver (see Paras 0018, 0203 and 0474) located in addressable communication with the light-emitting layer. See Paragraphs 0200-0233. Rothberg recites a well diameter of 20 nm to 1 micron in Paragraph 0210. Rothberg recites a device having up to 10 million wells, but Rothberg does not teach the specific well density wherein the solid support comprises addressable loci at a density of at least 10 x10⁶ addressable loci per cm². Rothberg also does not teach that each addressable locus supports synthesis of an oligonucleotide having a different sequence than oligonucleotides synthesized on the other addressable loci. Rothberg also does not teach a synthesis surface having a plurality of nucleosides attached wherein each nucleoside comprises a photolabile protecting group. Walt teaches a biosensor array. The embodiment of the device most relevant to the instant claims is shown in Figures 1-3 and described in columns 6-14. The biosensor array is comprised of a plurality of etched wells for holding cells. The array may include up to 100 million or 2 billion etched cells for holding cells or compounds for synthesis and analysis. The wells are formed in a square centimeter of space on a substrate. See columns 11 and 12 of Walt. Walt further teaches forming a library of compounds from a sample based on the use of a plurality of different nucleic acids in different wells in column 31, line 55 - column 33, line 60 of Walt. The Examiner submits it would have been obvious to one of ordinary skill in the art at the time of the effective date of the invention to combine the well density from the device of Walt with the device of Rothberg. One of ordinary skill in the art would add the well density to Rothenberg to provide an increased number of wells per square centimeter for high throughput analysis of compounds as taught by Walt. The Examiner further submits it would have been obvious to one of ordinary skill in the art at the time of the effective date of the invention to combine the use of different nucleic acid compounds in different wells from Walt with the device of Rothberg. One of ordinary skill in the art would add the different nucleic acid compounds in different wells to Rothberg to form a library of nucleotides or analytes from a sample as taught by Walt (see column 31, line 55 - column 33, line 60 of Walt). With respect to the new limitation of claim 45, the Examiner submits that Rothberg teaches a device having up to 10 million wells (Paragraph 0180) with each well having a single oligonucleotide (Paras 0160 and 0166). As previously noted, Walt teaches up to 2 billion cells on a substrate of a square centimeter. The Examiner submits the combination of Rothberg and Walt would result in a device capable of supporting synthesis of oligonucleotides at a density of about 1 oligonucleotide per 25 nm² to about 1 oligonucleotide per 75 nm² as recited in the claim. The combination of Rothberg and Walt does not teach a synthesis surface having a plurality of nucleosides attached wherein each nucleoside comprises a photolabile protecting group. Fodor teaches a method for light directed synthesis of oligonucleotides on a substrate. As shown in Figure 1 and described in columns 11-14, the method of Fodor includes providing a substrate having a plurality of regions having attached compounds for synthesis. The attached compounds include a photolabile protected group that is removed by irradiation. The substrate is then contacted with other compounds in the defined regions. The steps are repeated until the desired product is achieved. In columns 11-12, Fodor teaches the use of the photolabile protecting group allows control of which sites are available for reaction. Later, in columns 49-52, Fodor teaches photo protected nucleosides for use in nucleotide synthesis. The Examiner submits it would have been obvious to one of ordinary skill in the art at the time of the effective date of the invention to combine the nucleoside having a photolabile protecting group from Fodor with the combined teachings of Rothberg and Walt. One of ordinary skill in the art would add the photoprotected nucleosides to provide protected compounds for use during synthesis as taught by Fodor. Regarding claims 5, 6, 10 and 13 - Rothberg teaches the excitation source may provide visible radiation at a wavelength between about 350 nm and about 750 nm, near-infrared radiation at a wavelength between about 0.75 micron and about 1.4 microns, and/or short wavelength infrared radiation at a wavelength between about 1.4 microns and about 3 microns in Paragraph 0259. Regarding claims 18 and 46 - Rothberg recites a well depth of about 50 nm to about 500 nm in Paragraph 0210. Regarding claims 43, 47 and 48 - Rothberg discloses a transparent oxide layer (3-25/3-610/3- 620) having a roughened surface comprised of surface plasmon structures in Paragraphs 0217-and Figures 3-6 to 3-7F. Regarding claim 44 - Rothberg is silent as to the thickness of the transparent oxide layer, but teaches a silicon dioxide layer of about 150 nm in Paragraph 0382. The Examiner takes the position that the difference between the prior art is one of relative dimensions and the device. In Gardner V. TEC Syst., Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984), cert. denied, 469 U.S. 830, 225 USPQ 232 (1984), the Federal Circuit held that, where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device. Regarding claims 2, 3 and 49-53 - In Figure 4-3B and Paragraph 0280, Rothberg teaches an integrated semiconductor light emitting diode that may be fabricated adjacent to a sample well, in some implementations. A semiconductor LED may comprise a plurality of layers, as depicted in the drawing. The layers may include an electron transport layer 4-352, a hole blocking layer 4-354, and emissive layer 4-356, a hole transport layer 4-357, and an electron blocking layer 4-359, in some implementations. The stack of layers may be electrically contacted by an anode and cathode as described in connection with FIG. 4-3A. The LED structure depicted in FIG. 4-3B may be used for other types of LEDs, including but not limited to OLEDs, PhOLEDs, and a quantum dot LEDs (QLEDs). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DWAYNE K HANDY whose telephone number is (571)272-1259. The examiner can normally be reached M-F 10AM-7PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Capozzi can be reached at 571-270-3638. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DWAYNE K HANDY/Examiner, Art Unit 1798 September 18, 2026 /CHARLES CAPOZZI/Supervisory Patent Examiner, Art Unit 1798
Read full office action

Prosecution Timeline

Show 3 earlier events
Aug 13, 2025
Final Rejection mailed — §103
Dec 04, 2025
Request for Continued Examination
Dec 06, 2025
Response after Non-Final Action
Jan 23, 2026
Final Rejection mailed — §103
May 22, 2026
Applicant Interview (Telephonic)
Jun 23, 2026
Request for Continued Examination
Jun 24, 2026
Response after Non-Final Action
Sep 28, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774483
BIOSENSOR STRUCTURE FOR MEASURING SPECIMEN AND METHOD FOR MEASURING SPECIMEN BY USING THE SAME
3y 11m to grant Granted Oct 27, 2026
Patent 12766502
DEVICE AND METHOD FOR TESTING SERUM AND PLASMA SEPARATED FROM BLOOD CELLS IN WHOLE BLOOD SAMPLES
2y 2m to grant Granted Oct 20, 2026
Patent 12752271
GENE DETECTION SUBSTRATE, GENE DETECTION CHIP AND METHOD FOR PREPARING GENE DETECTION SAMPLE
3y 6m to grant Granted Oct 06, 2026
Patent 12709730
DATA-DRIVEN PREDICTIVE MODELING FOR CELL LINE SELECTION IN BIOPHARMACEUTICAL PRODUCTION
4y 9m to grant Granted Aug 18, 2026
Patent 12667840
Device And Method For Accelerated Material Extraction And Detection
1y 4m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
63%
Grant Probability
88%
With Interview (+24.9%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 762 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month